Project Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
177Lu-PSMA-617 abiraterone abiraterone acetate ADC ADT AI ai in healthcare antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA BRCA2 cancer immunotherapy CAR-T clinical trial crispr darolutamide docetaxel drug repurposing drug resistance enzalutamide HRR immunotherapy mcrpc metastatic hormone-sensitive prostate cancer mHSPC mRNA NEPC neuroendocrine prostate cancer olaparib oncolytic virus PARP1 PARP inhibitor Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data T-cell therapy
Latest Posts
- Darolutamide Linked to Better Real‑World Outcomes than Enzalutamide or Apalutamide in nmCRPC March 18, 2026
- AI CellVoyager Agent Turns Single‑Cell RNA‑seq Data into Continuous Hypothesis Generation March 18, 2026
- Ferroptosis-Nanoparticles Turn Prostate Tumors Hot: Docetaxel + Light Wakes Immunity March 18, 2026
- SonoPIN: Ultrasound‑Guided Microbubbles Deliver Large Cancer Drugs with Pinpoint Precision March 18, 2026
ARX517 Achieves Key Safety and Efficacy Milestones in Phase 1/2 Trials for Metastatic Castration-Resistant Prostate Cancer
/in Clinical Trial, Metastatic, Phase 1/by MaxDarolutamide Plus ADT: A Great Treatment Option for Metastatic Hormone-Sensitive Prostate Cancer
/in Clinical Trial, Metastatic, Phase 3/by MaxFirst-in-Class Targeted microRNA Therapy Slows Cancer Tumor Growth
/in Preclinical Research/by Max